USANA Health Sciences (USNA) 10-Q 11 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Apr. 02, 2022	May 06, 2022
Document Information [Line Items]
Entity Central Index Key	0000896264
Entity Registrant Name	USANA HEALTH SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 2, 2022
Document Transition Report	false
Entity File Number	001-35024
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0500306
Entity Address, Address Line One	3838 West Parkway Blvd.
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84120
City Area Code	801
Local Phone Number	954-7100
Title of 12(b) Security	Common Stock
Trading Symbol	USNA
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,188,123

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Apr. 02, 2022	Jan. 01, 2022
Current assets
Cash and cash equivalents	$ 237,753	$ 239,832
Inventories	97,581	98,318
Prepaid expenses and other current assets	28,451	26,967
Total current assets	363,785	365,117
Property and equipment, net	100,792	101,780
Goodwill	17,661	17,668
Intangible assets, net	30,124	30,442
Deferred tax assets	4,542	4,839
Other assets	56,015	57,894
Assets, Total	572,919	577,740
Current liabilities
Accounts payable	11,248	13,508
Line of credit	10,000	0
Other current liabilities	136,719	147,282
Total current liabilities	157,967	160,790
Deferred tax liabilities	11,419	7,497
Other long-term liabilities	13,587	14,329
Stockholders' equity
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 19,185 as of April 2, 2022 and 19,393 as of January 1, 2022	19	19
Additional paid-in capital	45,951	50,010
Retained earnings	344,755	344,637
Accumulated other comprehensive income (loss)	(779)	458
Total stockholders' equity	389,946	395,124
Liabilities and Equity, Total	$ 572,919	$ 577,740

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares shares in Thousands	Apr. 02, 2022	Jan. 01, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	19,185	19,393
Common stock, shares outstanding (in shares)	19,185	19,393

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Net sales	$ 272,867	$ 307,976
Cost of sales	51,383	57,651
Gross profit	221,484	250,325
Operating expenses:
Associate incentives	119,620	134,495
Selling, general and administrative	68,797	71,633
Total operating expenses	188,417	206,128
Earnings from operations	33,067	44,197
Other income (expense):
Interest income	739	760
Interest expense	(32)	(5)
Other, net	(487)	(616)
Other income (expense), net	220	139
Earnings before income taxes	33,287	44,336
Income taxes	10,818	13,715
Net earnings	$ 22,469	$ 30,621
Earnings per common share
Basic (in dollars per share)	$ 1.16	$ 1.47
Diluted (in dollars per share)	$ 1.15	$ 1.45
Weighted average common shares outstanding
Basic (in shares)	19,351	20,892
Diluted (in shares)	19,481	21,096
Comprehensive income:
Net earnings	$ 22,469	$ 30,621
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(691)	(2,531)
Tax benefit (expense) related to foreign currency translation adjustment	(546)	1,616
Other comprehensive income (loss), net of tax	(1,237)	(915)
Comprehensive income	$ 21,232	$ 29,706

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Jan. 02, 2021	21,038
Balance at Jan. 02, 2021	$ 21	$ 62,460	$ 382,794	$ (3,625)	$ 441,650
Net earnings			30,621		30,621
Other comprehensive income (loss), net of tax				(915)	(915)
Equity-based compensation expense		3,740			$ 3,740
Common stock repurchased and retired (in shares)	(721)				(721)
Common stock repurchased and retired	$ (1)	(9,251)	(60,202)		$ (69,454)
Common stock issued under equity award plans (in shares)	105
Common stock issued under equity award plans	$ 0				0
Tax withholding for net-share settled equity awards		(2,865)			(2,865)
Balance (in shares) at Apr. 03, 2021	20,422
Balance at Apr. 03, 2021	$ 20	54,084	353,213	(4,540)	$ 402,777
Balance (in shares) at Jan. 01, 2022	19,393				19,393
Balance at Jan. 01, 2022	$ 19	50,010	344,637	458	$ 395,124
Net earnings			22,469		22,469
Other comprehensive income (loss), net of tax				(1,237)	(1,237)
Equity-based compensation expense		3,183			$ 3,183
Common stock repurchased and retired (in shares)	(288)				(288)
Common stock repurchased and retired	$ 0	(3,031)	(22,351)		$ (25,382)
Common stock issued under equity award plans (in shares)	80
Common stock issued under equity award plans	$ 0				0
Tax withholding for net-share settled equity awards		(4,211)			$ (4,211)
Balance (in shares) at Apr. 02, 2022	19,185				19,185
Balance at Apr. 02, 2022	$ 19	$ 45,951	$ 344,755	$ (779)	$ 389,946

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Cash flows from operating activities
Net earnings	$ 22,469	$ 30,621
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities
Depreciation and amortization	3,279	3,231
Right-of-use asset amortization	2,327	2,259
(Gain) loss on sale of property and equipment	(3)	47
Equity-based compensation expense	3,183	3,740
Deferred income taxes	3,667	2,968
Changes in operating assets and liabilities:
Inventories	48	1,393
Prepaid expenses and other assets	(1,865)	(3,960)
Accounts payable	(2,153)	(6,899)
Other liabilities	(11,251)	(13,741)
Net cash provided by (used in) operating activities	19,701	19,659
Cash flows from investing activities
Receipts on notes receivable	0	51
Payments for net investment hedge	0	(1,555)
Proceeds from sale of property and equipment	3	13
Purchases of property and equipment	(1,789)	(1,597)
Net cash provided by (used in) investing activities	(1,786)	(3,088)
Cash flows from financing activities
Repurchase of common stock	(25,382)	(67,610)
Borrowings on line of credit	10,000	0
Payments related to tax withholding for net-share settled equity awards	(4,211)	(2,865)
Net cash provided by (used in) financing activities	(19,593)	(70,475)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(403)	(1,962)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(2,081)	(55,866)
Cash, cash equivalents, and restricted cash at beginning of period	243,653	315,937
Cash, cash equivalents, and restricted cash at end of period	241,572	260,071
Cash and cash equivalents	237,753	256,964
Cash, cash equivalents, and restricted cash at end of period	241,572	260,071
Supplemental disclosures of cash flow information
Interest	5	3
Income taxes	8,347	13,523
Cash received during the period for:
Income tax refund	25	0
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations	289	829
Accrued purchases of property and equipment	285	239
Unsettled trades for repurchase of common stock	0	1,844
Prepaid Expenses and Other Current Assets [Member]
Cash flows from financing activities
Restricted cash	0	61
Other Noncurrent Assets [Member]
Cash flows from financing activities
Restricted cash	$ 3,819	$ 3,046

Note A - Organization, Consolid

Note A - Organization, Consolidation, and Basis of Presentation	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE A – ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION The COVID- 19 19 not three April 2, 2022 2021. 19 USANA Health Sciences, Inc. develops and manufactures high quality, science-based nutritional and personal care products that are sold internationally through a direct selling channel. The Condensed Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, which are grouped and presented in two 1 2 three ( 1 (i) Greater China - Hong Kong, Taiwan, and China. The Company’s business in China is conducted by BabyCare Holdings, Ltd., the Company’s wholly-owned subsidiary. (ii) Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia. (iii) North Asia – Japan and South Korea. ( 2 The condensed consolidated balance sheet as of January 1, 2022 10 10 01 X April 2, 2022 three April 2, 2022 April 3, 2021 The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 10 January 1, 2022 three April 2, 2022 not may December 31, 2022 Recent Accounting Pronouncements There were no three April 2, 2022

Note B - Fair Value Measures

Note B - Fair Value Measures	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE B – FAIR VALUE MEASURES The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are: ● Level 1 ● Level 2 1 ● Level 3 As of April 2, 2022 January 1, 2022 Fair Value Measurements Using April 2, Inputs 2022 Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 164,519 $ 164,519 $ — $ — Net investment hedge included in other current liabilities (470 ) — (470 ) — Foreign currency contracts included in other current liabilities (16 ) — (16 ) — $ 164,033 $ 164,519 $ (486 ) $ — Fair Value Measurements Using January 1, Inputs 2022 Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 163,619 $ 163,619 $ — $ — Foreign currency contracts included in other current liabilities (461 ) — (461 ) — $ 163,158 $ 163,619 $ (461 ) $ — There were no The majority of the Company’s non-financial assets, which include long-lived assets, are not April 2, 2022 January 1, 2022 The Company’s financial instruments include cash equivalents, restricted cash, and foreign currency contracts. The recorded values of cash equivalents and restricted cash approximate their fair values, based on their short-term nature.

Note C - Inventories

Note C - Inventories	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE C – INVENTORIES Inventories consist of the following: April 2, January 1, 2022 2022 Raw materials $ 30,591 $ 30,280 Work in progress 9,734 9,586 Finished goods 57,256 58,452 $ 97,581 $ 98,318

Note D - Investment in Equity S

Note D - Investment in Equity Securities	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Investments in Equity Securities [Text Block]	NOTE D – INVESTMENT IN EQUITY SECURITIES As of April 2, 2022 January 1, 2022 was $20,000 an During the three April 2, 2022 January 1, 2022

Note E - Revenue and Contract L

Note E - Revenue and Contract Liabilities	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE E – REVENUE AND CONTRACT LIABILITIES Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred as goods are delivered to the third Other revenue includes fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and annual account renewal fees for Associates, for which control is transferred over time as services are delivered and are recognized as revenue on a straight-line basis over the term of the respective contracts. The following table presents Other Revenue for the periods indicated: Quarter Ended April 2, April 3, 2022 2021 Other Revenue $ 899 $ 972 Disaggregation of revenue by geographic region and major product line is included in Segment Information in Note J. The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period. Contract liabilities are included in the "Other current liabilities" line item on the Company's condensed consolidated balance sheets: April 2, January 1, 2022 2022 Contract liabilities at beginning of period $ 19,635 $ 15,952 Increase due to deferral of revenue at end of period 17,183 19,635 Decrease due to beginning contract liabilities recognized as revenue (15,939 ) (15,952 ) Contract liabilities at end of period $ 20,879 $ 19,635

Note F - Line of Credit

Note F - Line of Credit	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE F – LINE OF CREDIT On August 25, 2020, ” ” April 21, 2021, ” ” ” The Credit Agreement provides for a revolving credit limit for loans to the Company up to $75,000 (the “Credit Facility ” may As of April 2, 2022 Interest on revolving borrowings under the Credit Facility are computed at Bank of America’s prime rate or the Eurodollar rate, adjusted by features specified in the Credit Agreement. The Credit Agreement covenants require the Company’s rolling four 1.0 not The Company will be required to pay any balance on this Credit Facility in full at the time of maturity in August 2025.

Note G - Contingencies

Note G - Contingencies	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE G – CONTINGENCIES The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving its products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given as to the outcome of these proceedings, management does not

Note H - Derivative Financial I

Note H - Derivative Financial Instruments	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE H – DERIVATIVE FINANCIAL INSTRUMENTS The Company’s risk management strategy includes the select use of derivative instruments to reduce the effects of volatility in foreign currency exchange exposure on operating results and cash flows. In accordance with the Company’s risk management policies, the Company does not The Company periodically uses derivative instruments to hedge the foreign currency exposure of its net investment in foreign subsidiaries into U.S. dollars. Initially, the Company records derivative assets on a gross basis in its condensed consolidated balance sheets. Subsequently the fair value of derivatives is measured for each reporting period. The effective portion of gains and losses attributable to these net investment hedges is recorded to foreign currency translation adjustment (“FCTA”) within accumulated other comprehensive income (loss) (“AOCI”) to offset the change in the carrying value of the net investment being hedged and will subsequently be reclassified to net earnings in the period in which the investment in the subsidiary is either sold or substantially liquidated. During the three April 2, 2022 three April 3, 2021 three April 2, 2022 April 3, 2021

Note I - Common Stock and Earni

Note I - Common Stock and Earnings Per Share	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE I – COMMON STOCK AND EARNINGS PER SHARE Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated: Quarter Ended April 2, April 3, 2022 2021 Net earnings available to common shareholders $ 22,469 $ 30,621 Weighted average common shares outstanding - basic 19,351 20,892 Dilutive effect of in-the-money equity awards 130 204 Weighted average common shares outstanding - diluted 19,481 21,096 Earnings per common share from net earnings - basic $ 1.16 $ 1.47 Earnings per common share from net earnings - diluted $ 1.15 $ 1.45 Equity awards for the following shares were not Quarter Ended April 2, April 3, 2022 2021 170 57 During the three April 2, 2022 April 3, 2021 As of April 2, 2022 no no

Note J - Segment Information

Note J - Segment Information	3 Months Ended
	Apr. 02, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE J – SEGMENT INFORMATION USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products that are sold through a network marketing system of independent distributors (“Associates”). The Company aggregates its operating segments into one reportable segment, as management believes that the Company’s segments exhibit similar long-term financial performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No 10% Quarter Ended April 2, April 3, 2022 2021 USANA® Nutritionals 87 % 87 % USANA Foods(1) 7 % 7 % Personal care and Skincare 5 % 5 % All Other 1 % 1 % ( 1 Includes the Company’s new Active Nutrition line, which launched in five 2021 Selected Financial Information Financial information, presented by geographic region is listed below: Quarter Ended April 2, April 3, 2022 2021 Net Sales to External Customers Asia Pacific Greater China $ 133,739 $ 148,978 Southeast Asia Pacific 54,742 72,148 North Asia 29,939 30,165 Asia Pacific Total 218,420 251,291 Americas and Europe 54,447 56,685 Consolidated Total $ 272,867 $ 307,976 The following table provides further information on markets representing ten Quarter Ended April 2, April 3, 2022 2021 Net sales: China $ 120,254 $ 134,303 South Korea $ 29,187 $ 29,020 United States $ 28,277 $ 26,963 As of April 2, January 1, 2022 2022 Long-lived assets: China $ 90,196 $ 91,530 United States $ 85,221 $ 85,350

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 02, 2022
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There were no three April 2, 2022

Note B - Fair Value Measures (T

Note B - Fair Value Measures (Tables)	3 Months Ended
	Apr. 02, 2022
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Fair Value Measurements Using April 2, Inputs 2022 Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 164,519 $ 164,519 $ — $ — Net investment hedge included in other current liabilities (470 ) — (470 ) — Foreign currency contracts included in other current liabilities (16 ) — (16 ) — $ 164,033 $ 164,519 $ (486 ) $ — Fair Value Measurements Using January 1, Inputs 2022 Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 163,619 $ 163,619 $ — $ — Foreign currency contracts included in other current liabilities (461 ) — (461 ) — $ 163,158 $ 163,619 $ (461 ) $ —

Note C - Inventories (Tables)

Note C - Inventories (Tables)	3 Months Ended
	Apr. 02, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	April 2, January 1, 2022 2022 Raw materials $ 30,591 $ 30,280 Work in progress 9,734 9,586 Finished goods 57,256 58,452 $ 97,581 $ 98,318

Note E - Revenue and Contract_2

Note E - Revenue and Contract Liabilities (Tables)	3 Months Ended
	Apr. 02, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 Other Revenue $ 899 $ 972
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	April 2, January 1, 2022 2022 Contract liabilities at beginning of period $ 19,635 $ 15,952 Increase due to deferral of revenue at end of period 17,183 19,635 Decrease due to beginning contract liabilities recognized as revenue (15,939 ) (15,952 ) Contract liabilities at end of period $ 20,879 $ 19,635

Note I - Common Stock and Ear_2

Note I - Common Stock and Earnings Per Share (Tables)	3 Months Ended
	Apr. 02, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 Net earnings available to common shareholders $ 22,469 $ 30,621 Weighted average common shares outstanding - basic 19,351 20,892 Dilutive effect of in-the-money equity awards 130 204 Weighted average common shares outstanding - diluted 19,481 21,096 Earnings per common share from net earnings - basic $ 1.16 $ 1.47 Earnings per common share from net earnings - diluted $ 1.15 $ 1.45
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 170 57

Note J - Segment Information (T

Note J - Segment Information (Tables)	3 Months Ended
	Apr. 02, 2022
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 USANA® Nutritionals 87 % 87 % USANA Foods(1) 7 % 7 % Personal care and Skincare 5 % 5 % All Other 1 % 1 %
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 Net Sales to External Customers Asia Pacific Greater China $ 133,739 $ 148,978 Southeast Asia Pacific 54,742 72,148 North Asia 29,939 30,165 Asia Pacific Total 218,420 251,291 Americas and Europe 54,447 56,685 Consolidated Total $ 272,867 $ 307,976
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Quarter Ended April 2, April 3, 2022 2021 Net sales: China $ 120,254 $ 134,303 South Korea $ 29,187 $ 29,020 United States $ 28,277 $ 26,963 As of April 2, January 1, 2022 2022 Long-lived assets: China $ 90,196 $ 91,530 United States $ 85,221 $ 85,350

Note A - Organization, Consol_2

Note A - Organization, Consolidation, and Basis of Presentation (Details Textual)	3 Months Ended
	Apr. 02, 2022
Number of Geographic Regions	2
Number of Sub Geographical Regions	3

Note B - Fair Value Measures (D

Note B - Fair Value Measures (Details Textual) - USD ($) $ in Thousands	Apr. 02, 2022	Jan. 01, 2022
Nonfinancial Assets, Fair Value Disclosure	$ 0	$ 0

Note B - Fair Value Measures -

Note B - Fair Value Measures - Schedule Of Assets And Liabilities Measured At Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Apr. 02, 2022	Jan. 01, 2022
Foreign currency contracts included in other current liabilities	$ (16)	$ (461)
Fair Value, Net Asset (Liability), Total	164,033	163,158
Foreign currency contracts included in other current liabilities	(16)	(461)
Designated as Hedging Instrument [Member]
Net investment hedge included in other current liabilities	(470)
Fair Value, Inputs, Level 1 [Member]
Foreign currency contracts included in other current liabilities	0	0
Fair Value, Net Asset (Liability), Total	164,519	163,619
Foreign currency contracts included in other current liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Designated as Hedging Instrument [Member]
Net investment hedge included in other current liabilities	0
Fair Value, Inputs, Level 2 [Member]
Foreign currency contracts included in other current liabilities	(16)	(461)
Fair Value, Net Asset (Liability), Total	(486)	(461)
Foreign currency contracts included in other current liabilities	(16)	(461)
Fair Value, Inputs, Level 2 [Member] | Designated as Hedging Instrument [Member]
Net investment hedge included in other current liabilities	(470)
Fair Value, Inputs, Level 3 [Member]
Foreign currency contracts included in other current liabilities	0	0
Fair Value, Net Asset (Liability), Total	0	0
Foreign currency contracts included in other current liabilities	0	0
Fair Value, Inputs, Level 3 [Member] | Designated as Hedging Instrument [Member]
Net investment hedge included in other current liabilities	0
Money Market Funds [Member]
Money market funds included in cash equivalents	164,519	163,619
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market funds included in cash equivalents	164,519	163,619
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market funds included in cash equivalents	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market funds included in cash equivalents	$ 0	$ 0

Note C - Inventories - Schedule

Note C - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Apr. 02, 2022	Jan. 01, 2022
Raw materials	$ 30,591	$ 30,280
Work in progress	9,734	9,586
Finished goods	57,256	58,452
Inventory, Net, Total	$ 97,581	$ 98,318

Note D - Investment in Equity_2

Note D - Investment in Equity Securities (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2022	Jan. 01, 2022
Equity Securities without Readily Determinable Fair Value, Price Adjustment, Cumulative Amount	$ 0	$ 0
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount	0	0
Other Assets [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 20,000	$ 20,000

Note E - Revenue and Contract_3

Note E - Revenue and Contract Liabilities - Schedule of Other Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Other Revenue	$ 899	$ 972

Note E - Revenue and Contract_4

Note E - Revenue and Contract Liabilities - Schedule Of Contract Liabilities From Contract With Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Jan. 01, 2022
Contract liabilities at beginning of period	$ 19,635	$ 15,952
Increase due to deferral of revenue at end of period	17,183	19,635
Decrease due to beginning contract liabilities recognized as revenue	(15,939)	(15,952)
Contract liabilities at end of period	$ 20,879	$ 19,635

Note F - Line of Credit (Detail

Note F - Line of Credit (Details Textual) - Line of Credit [Member] $ in Millions	3 Months Ended
	Apr. 02, 2022USD ($)
Line of Credit Facility, Maximum Borrowing Capacity	$ 75
Line of Credit Facility, Additional Increase in Maximum Borrowing Capacity	200
Long-term Line of Credit, Total	10
Amended and Restated Credit Agreement [Member]
Debt Instrument Covenant, Adjusted Earnings Before Interest Taxes, Depreciation, and Amortization	$ 100
Debt Instrument, Covenant Ratio of Consolidated Funded Debt to Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization	2

Note H - Derivative Financial_2

Note H - Derivative Financial Instruments (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Derivative, Notional Amount	$ 98,930	$ 98,684
Derivative, Loss on Derivative	$ 470
Derivative, Gain on Derivative		$ 190

Note I - Common Stock and Ear_3

Note I - Common Stock and Earnings Per Share (Details Textual) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Stock Repurchased and Retired During Period, Shares (in shares)	288	721
Stock Repurchased and Retired During Period, Value	$ 25,382	$ 69,454
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 82,839

Note I - Common Stock and Ear_4

Note I - Common Stock and Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Net earnings available to common shareholders	$ 22,469	$ 30,621
Weighted average common shares outstanding - basic (in shares)	19,351	20,892
Dilutive effect of in-the-money equity awards (in shares)	130	204
Weighted average common shares outstanding - diluted (in shares)	19,481	21,096
Earnings per common share from net earnings - basic (in dollars per share)	$ 1.16	$ 1.47
Earnings per common share from net earnings - diluted (in dollars per share)	$ 1.15	$ 1.45

Note I - Common Stock and Ear_5

Note I - Common Stock and Earnings Per Share - Schedule of Shares not Included in the Computation of Diluted EPS (Details) - shares shares in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Anti-dilutive equity awards (in shares)	170	57

Note J - Segment Information (D

Note J - Segment Information (Details Textual)	3 Months Ended
	Apr. 02, 2022
Number of Reportable Segments	1

Note J - Segment Information -

Note J - Segment Information - Schedule of Revenue Percentage By Product (Details) - Product Concentration Risk [Member] - Revenue Benchmark [Member]		3 Months Ended
		Apr. 02, 2022	Apr. 03, 2021
USANA Nutritionals [Member]
Percentage of product revenue		87.00%	87.00%
USANA Foods [Member]
Percentage of product revenue	[1]	7.00%	7.00%
Personal Care and Skincare [Member]
Percentage of product revenue		5.00%	5.00%
All Other [Member]
Percentage of product revenue		1.00%	1.00%
[1]	Includes the Company's new Active Nutrition line, which launched in five markets in 2021 and will roll out to additional markets in future periods.

Note J - Segment Information _2

Note J - Segment Information - Revenues From External Customers by Geographical Areas (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021
Net Sales to External Customers	$ 272,867	$ 307,976
Greater China [Member]
Net Sales to External Customers	133,739	148,978
Southeast Asia Pacific [Member]
Net Sales to External Customers	54,742	72,148
North Asia [Member]
Net Sales to External Customers	29,939	30,165
Asia Pacific [Member]
Net Sales to External Customers	218,420	251,291
Americas and Europe [Member]
Net Sales to External Customers	$ 54,447	$ 56,685

Note J - Segment Information _3

Note J - Segment Information - Consolidated Net Sales and Long Lived Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2022	Apr. 03, 2021	Jan. 01, 2022
Net sales	$ 272,867	$ 307,976
CHINA
Net sales	120,254	134,303
Long-lived assets	90,196		$ 91,530
KOREA, REPUBLIC OF
Net sales	29,187	29,020
UNITED STATES
Net sales	28,277	$ 26,963
Long-lived assets	$ 85,221		$ 85,350